The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
Official Title: A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)
Study ID: NCT01771146
Brief Summary: A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)
Detailed Description: Patients with pancreas cancer will be enrolled and treated with a planned course of 6 cycles (3 months) of chemotherapy with FOLFIRINOX prior to undergoing surgical resection.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Baylor University Medical Center - Texas Oncology, Dallas, Texas, United States
Name: Scott Celinski, MD
Affiliation: Baylor Health Care System
Role: PRINCIPAL_INVESTIGATOR